1-247424386-A-G
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 3P and 10B. PM1PP2BP4_ModerateBS1BS2
The NM_001243133.2(NLRP3):c.937A>G(p.Ile313Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000191 in 1,613,896 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. I313T) has been classified as Uncertain significance.
Frequency
Consequence
NM_001243133.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NLRP3 | NM_001243133.2 | c.937A>G | p.Ile313Val | missense_variant | 4/10 | ENST00000336119.8 | NP_001230062.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NLRP3 | ENST00000336119.8 | c.937A>G | p.Ile313Val | missense_variant | 4/10 | 1 | NM_001243133.2 | ENSP00000337383.4 |
Frequencies
GnomAD3 genomes AF: 0.000138 AC: 21AN: 152022Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000227 AC: 57AN: 250946Hom.: 0 AF XY: 0.000251 AC XY: 34AN XY: 135666
GnomAD4 exome AF: 0.000196 AC: 287AN: 1461874Hom.: 0 Cov.: 43 AF XY: 0.000193 AC XY: 140AN XY: 727240
GnomAD4 genome AF: 0.000138 AC: 21AN: 152022Hom.: 0 Cov.: 32 AF XY: 0.000175 AC XY: 13AN XY: 74264
ClinVar
Submissions by phenotype
not provided Uncertain:3
Uncertain significance, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 12, 2022 | Identified in additional patients with suspected CAPS or systemic auto-inflammatory disorders in published literature, although detailed clinical information is not available (Cuisset et al., 2011; Rusmini et al., 2015); In silico analysis supports that this missense variant does not alter protein structure/function; Also known as p.(I313V); This variant is associated with the following publications: (PMID: 32082075, 32199921, 34426522, 28814775, 19302049, 21109514, 26386126, 27191192) - |
Uncertain significance, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Sep 13, 2018 | Variant classified as Uncertain Significance - Favor Benign. The p.Ile315Val var iant in NLRP3 has been reported (as p.Ile313Val) in 1 individual with CAPS, and segregated with disease in at least 3 affected family members (Cuisset 2011). It was also reported in one individual with mevalonate kinase deficiency who carri ed additional variants in the MKV gene that were sufficient to explain their phe notype (Rusmini 2016). This variant has also been identified in 0.05% (58/126272 ) of European chromosomes by the Genome Aggregation Database (gnomAD; http://gno mad.broadinstitute.org/). Computational prediction tools and conservation analys is suggest that an isoleucine to valine change at position 315 may not impact th e protein, though this information is not predictive enough to rule out pathogen icity. On the other hand, additional computational tools suggest that this varia nt may create a novel splice site; however, this prediction may not reflect biol ogical function. In summary, while its frequency suggests that it is more likely to be benign, the clinical significance of the p.Ile315Val variant is uncertain due to the presence of conflicting data. ACMG/AMP Criteria applied: BS1, PP1. - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | May 09, 2019 | The NLRP3 c.943A>G; p.Ile315Val variant (rs180177501) is reported in the medical literature in individuals with cryopyrin-associated periodic syndrome and segregating with disease in at least one family (Cuisset 2011, Rusmini 2016). The variant is reported in the ClinVar database as a variant of uncertain significance (Variation ID: 97989) and an expert panel considers this variant to be of uncertain significance (Van Gijn 2018). The variant is reported in the European (non-Finnish population) with an allele frequency of 0.05% (61/128760 alleles) in the Genome Aggregation Database. The isoleucine at this position is moderately conserved and computational algorithms (PolyPhen-2, SIFT) predicts this variant is tolerated. However, most known pathogenic NLRP3 variants occur in this region (Masters 2009). Given the lack of clinical and functional data, the significance of the variant is uncertain at this time. References: Cuisset L et al. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis. 2011 Mar;70(3):495-9. Masters SL et al. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*).Annu Rev Immunol. 2009;27:621-68. Rusmini M et al. Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases. Ann Rheum Dis. 2016 Aug;75(8):1550-7. Van Gijn ME et al. New workflow for classification of genetic variants' pathogenicity applied to hereditary recurrent fevers by the International Study Group for Systemic Autoinflammatory Diseases (INSAID). J Med Genet. 2018 Aug;55(8):530-537. - |
Familial cold autoinflammatory syndrome 1 Benign:1Other:1
not provided, no classification provided | literature only | Unité médicale des maladies autoinflammatoires, CHRU Montpellier | - | - - |
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 17, 2021 | The c.943A>G (p.I315V) alteration is located in exon 3 (coding exon 3) of the NLRP3 gene. This alteration results from a A to G substitution at nucleotide position 943, causing the isoleucine (I) at amino acid position 315 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Familial amyloid nephropathy with urticaria AND deafness;C0409818:Chronic infantile neurological, cutaneous and articular syndrome;C1835697:Keratitis fugax hereditaria;C4521680:Hearing loss, autosomal dominant 34, with or without inflammation;C4551895:Familial cold autoinflammatory syndrome 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 05, 2024 | - - |
Autoinflammatory syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | Jan 12, 2021 | - - |
Cryopyrin associated periodic syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 28, 2023 | - - |
Familial amyloid nephropathy with urticaria AND deafness Benign:1
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign. - |
Chronic infantile neurological, cutaneous and articular syndrome Benign:1
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at